Skip to main content

Table 3 Common types of STOPPFrail-PIM at pre-admission and at discharge

From: Prevalence of potentially inappropriate medications based on the STOPPFrail criteria in frail older patients with limited life expectancy: a cross-sectional study

STOPPFrail Criteria Section Instance (n) Reduction rate (%) p-value
Admission Discharge
A2 Any drug without clear clinical indication 413 22 94.7  < 0.001
B1 Lipid lowering therapies 66 58 12.1 0.088
D1 Neuroleptic antipsychotics 50 32 36.0 0.001
C1 Anti-platelet for primary prevention 41 19 53.7  < 0.001
I1 Diabetic oral agents for stringent control 27 35 -29.6 0.131
G1 Calcium supplementation 21 18 14.3 0.468
D2 Memantine without BPSD 21 16 23.8 0.025
J1 Multivitamins 17 13 23.5 0.395
E2 High-dose H2RA (full therapeutic dose with ≥ 8 weeks) 13 4 69.2 0.012
G4 Long-term oral NSAIDs (≥ 2 months) 13 2 84.6 0.001
E1 High-dose PPI (full therapeutic dose with ≥ 8 weeks) 9 11 -22.2 0.594
H2 Alpha blockers with urinary bladder catherization 5 5 0 1.000
G2 Anti-resorptive/bone anabolic drugs for osteoporosis 4 1 75.0 0.083
E3 Gastrointestinal antispasmodics 3 1 66.7 0.158
G5 Long-term oral steroids
(≥ 2 months)
3 4 -33.3 0.565
F1 Theophylline use other than asthma 2 1 50.0 0.319
J2 Nutritional supplements 2 3 -50.0 0.707
A1 Any drug that patient persistently fails to take or tolerate 1 0 100 0.319
B2 Alpha-blockers for hypertension 1 0 100 0.319
F2 Leukotriene antagonists 1 0 100 0.319
G3 SERMs for osteoporosis 1 0 100 0.319
H1 5-Alpha reductase inhibitors with urinary bladder catherization 0 0   
H3 Muscarinic antagonist with urinary bladder catherization 0 0   
I2 ACE-inhibitors for diabetic nephropathy 0 0   
I3 Angiotensin receptor blockers for diabetic nephropathy 0 0   
I4 Systemic estrogens for menopausal symptoms 0 0   
J3 Prophylactic antibiotics 0 0   
Total 714 245 65.7  < 0.001
  1. STOPPFrail-PIM: potentially inappropriate medication according to STOPPFrail (Screening Tool of Older Persons’ Prescriptions in Frail adults with a limited life expectancy) criteria
  2. BPSD, behavioral and psychiatric symptoms of dementia; H2RA, H2 receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PPI, proton pump inhibitor; SERM, selective estrogen receptor modulator; ACE, angiotensin converting enzyme